BMRN NASDAQ
BioMarin Pharmaceutical Inc.
1W: -1.9%
1M: -6.9%
3M: -9.8%
YTD: -6.9%
1Y: +1.6%
3Y: -32.6%
5Y: -25.3%
$55.35
-0.40 (-0.72%)
Weekly Expected Move ±3.9%
$52
$54
$56
$58
$60
Credit Risk of going bust: lower than 58% of companies Debt: 28.2% of company value Bonds: $170.1M held by 149 funds, 129 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.66 (down 97%), BioMarin Pharmaceutical Inc. would be worth roughly what it owes.
Total debt $4.20B against a stock market value of $10.71B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.42B (short-term plus half of long-term), stock volatility 34.6%; Altman Z'' 2.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.66 (down 97%), BioMarin Pharmaceutical Inc. would be worth roughly what it owes.
Total debt $4.20B against a stock market value of $10.71B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.42B (short-term plus half of long-term), stock volatility 34.6%; Altman Z'' 2.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.30
Neutral
1 bullish
0 neutral
2 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Crossmark Global Holdings Inc.
Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN
Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BioMarin Q3 financial results to see IPR&D expense impact of $283M
What's next for personalized mRNA cancer vaccines?
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
BioMarin Stops Voxzogo Development for Noonan Syndrome
BioMarin Pharmaceutical Inc. $BMRN Stock Position Raised by California State Teachers Retirement System
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Amundi
Ten healthcare stocks with A-rated valuations and strong revenue growth
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Hsbc Holdings PLC
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
Connor Clark & Lunn Investment Management Ltd. Makes New $546,000 Investment in BioMarin Pharmaceutical Inc. $BMRN
Bank of New York Mellon Corp Makes New $66.11 Million Investment in BioMarin Pharmaceutical Inc. $BMRN
ADAR1 Capital Management LLC Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN
BioMarin initiated an outperform at BMO as Voxzogo erosion overstated
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries
5 Undervalued Price-to-Book Stocks Worth Buying in August
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Assenagon Asset Management S.A.
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates
Amundi Cuts Position in BioMarin Pharmaceutical Inc. $BMRN
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
Bank of New York Mellon Corp Sells 631,362 Shares of BioMarin Pharmaceutical Inc. $BMRN
D.A. Davidson & CO. Acquires 36,293 Shares of BioMarin Pharmaceutical Inc. $BMRN
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin Reveals Dwarfism Study Data, Stock Soars
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
BioMarin gains on Voxzogo phase 3 results
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BioMarin outlines $3.825B-$3.925B 2026 revenue outlook driven by Amicus integration and 20% growth target
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics
BioMarin (BMRN) Q1 2026 Earnings Transcript
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
BioMarin Reports First Quarter 2026 Financial and Operating Results
BioMarin (BMRN) Q4 2025 Earnings Transcript
Here are the major earnings after the close Monday
Earnings Scheduled For May 4, 2026
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioMarin Pharmaceutical Inc. $BMRN Stake Cut by Asset Management One Co. Ltd.
Cwm LLC Sells 77,791 Shares of BioMarin Pharmaceutical Inc. $BMRN
Choreo LLC Has $313,000 Holdings in BioMarin Pharmaceutical Inc. $BMRN
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN
Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports
BioMarin Pharmaceutical Inc. $BMRN Stake Boosted by Diversified Trust Co.
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN
Top 3 Health Care Stocks That Are Set To Fly In March
BioMarin shares drop 4% as Voxzogo trials are discontinued
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
EVP Of BioMarin Pharmaceutical Sold $996K In Stock
Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Do Options Traders Know Something About BMRN Stock We Don't?
Fisher Asset Management LLC Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc.
Andra AP fonden Acquires 105,000 Shares of BioMarin Pharmaceutical Inc. $BMRN
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
BioMarin to Participate in Four Upcoming Investor Conferences in March
BioMarin signals $3.325B–$3.425B 2026 revenue target as acquisitions and pipeline drive growth
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.10, revenue of $875M beats by $39.97M
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
Rare disease pharmas could benefit from FDA guidance to accelerate development
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
Here are the major earnings after the close Monday
Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more
BioMarin Pharmaceutical Q4 2025 Earnings Preview
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
BioMarin Announces Closing of Private Offering of Senior Notes
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline
Plato Investment Management Ltd Boosts Holdings in BioMarin Pharmaceutical Inc. $BMRN
Principal Financial Group Inc. Sells 13,638 Shares of BioMarin Pharmaceutical Inc. $BMRN
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Savant Capital LLC